Chronos-1 study investigates the efficacy and safety of copanlisib for Non-Hodgkin lymphoma patient.
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. The disease cause is unknown. The incidence of NHLs is increasing in many regions. Over two-thirds of patients are 60 years and older. NHL can be divided in indolent and aggressive lymphomas. Aggressive lymphomas are characterized by an aggressive clinical course if not immediately treated. However, with modern treatments and stem cell transplantation the disease can be cured in 50- 60% of patients. Patients with indolent Non-Hodgkin lymphomas have a median survival expectation of more than 10 years, even if the disease is incurable.
The aim of the study is to evaluate the efficacy and safety of copanlisib in patients with B-cell NHL relapsed or refractory to widely used approved therapies in standard practice.
Copanlisib is a selective Class I phosphoinositide 3-kinase inhibitor (PI3K). PI3K isoforms trigger many cellular functions such as growth control, metabolism and transcription initiation. PI3K is expressed in most lymphoid tumors. Selective inhibitors of PI3K are not strongly cytotoxic in vitro. However, the PI3K-targeted compound CAL-101 has achieved clinical responses in follicular lymphoma.
Luxembourg participates with two sites, Centre Hospitalier de Luxembourg (CHL) and the Centre Hospitalier Emile Mayrisch (CHEM) in the CHRONOS-1 study. CIEC-LIH supports the physicians participating in this study. Globally, it is planned to enrol 120 patients and approximately 1-3 patients in Luxembourg with relapsed/refractory indolent or aggressive non-hodgkin’s lymphoma.
More information are available here: www.luxclin.lu/Studies/Details/?c=STP4677ASY
for articles/videos/studies
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.
